Systematic Reviews
Copyright ©The Author(s) 2024. Published by Baishideng Publishing Group Inc. All rights reserved.
World J Gastroenterol. Mar 7, 2024; 30(9): 1213-1223
Published online Mar 7, 2024. doi: 10.3748/wjg.v30.i9.1213
Treatment of Helicobacter pylori with potassium competitive acid blockers: A systematic review and meta-analysis
Joseph Edwin Kanu, Jonathan Soldera
Joseph Edwin Kanu, Jonathan Soldera, Post Graduate Program at Acute Medicine and Gastroenterology, University of South Wales, Cardiff CF37 1DL, United Kingdom
Author contributions: All authors contributed to study concept and design, drafting the manuscript, contributed to the data acquisition, analysis and interpretation and critical revision of the manuscript for important intellectual content. Soldera J suppervised the study.
Conflict-of-interest statement: All the authors report no relevant conflicts of interest for this article.
PRISMA 2009 Checklist statement: The authors have read the PRISMA 2009 Checklist, and the manuscript was prepared and revised according to the PRISMA 2009 Checklist.
Open-Access: This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: https://creativecommons.org/Licenses/by-nc/4.0/
Corresponding author: Jonathan Soldera, MD, PhD, Instructor, Post Graduate Program at Acute Medicine and Gastroenterology, University of South Wales, Llantwit Rd, Pontypridd, Cardiff CF37 1DL, United Kingdom. jonathansoldera@gmail.com
Received: November 26, 2023
Peer-review started: November 26, 2023
First decision: December 25, 2023
Revised: December 28, 2023
Accepted: February 5, 2024
Article in press: February 5, 2024
Published online: March 7, 2024
Processing time: 101 Days and 4.9 Hours
Core Tip

Core Tip: In the systematic review and meta-analysis on the treatment of Helicobacter pylori (H. pylori) with potassium competitive acid blockers, vonoprazan-based triple therapy demonstrated superior efficacy over conventional proton pump inhibitor (PPI)-based triple therapy, establishing itself as a highly effective first-line regimen. Conversely, tegoprazan-based triple therapy was found to be non-inferior to classical PPI triple therapy. These findings signify a potential paradigm shift in H. pylori eradication strategies.